Skip to content
View in the app

A better way to browse. Learn more.

Thailand News and Discussion Forum | ASEANNOW

A full-screen app on your home screen with push notifications, badges and more.

To install this app on iOS and iPadOS
  1. Tap the Share icon in Safari
  2. Scroll the menu and tap Add to Home Screen.
  3. Tap Add in the top-right corner.
To install this app on Android
  1. Tap the 3-dot menu (⋮) in the top-right corner of the browser.
  2. Tap Add to Home screen or Install app.
  3. Confirm by tapping Install.

RSV vax for older adults 92% protective against poor outcomes

Featured Replies

RSV vaccine for older adults 92% protective against poor outcomes, real-world study estimates

October 23, 2025

 

"In its first year of use in the United States, the overall estimated effectiveness of the respiratory syncytial virus (RSV) vaccine against respiratory illness and severe disease in adults aged 60 years and older was 92%, a team led by researchers from Kaiser Permanente Southern California and vaccine maker Pfizer reported yesterday in Clinical Infectious Diseases.

 

The investigators used a test-negative case-control design to estimate the vaccine effectiveness (VE) of the RSVpreF (Abrysvo) vaccine against emergency department (ED) visits or hospitalizations among 696 older RSV patients, 6,540 healthy ("broad") controls, and 1,034 who tested positive only for a non–vaccine-preventable pathogen ("strict" controls) from November 2023 to April 2024.

 

In June 2024, the US Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) recommended that all adults aged 75 and older and those aged 60 to 74 at high risk for severe RSV receive a single dose of the vaccine. But uptake has been low. By December 2024, estimated US coverage of RSV vaccines was 34% among adults aged 75 and older and 31% in high-risk patients aged 60 to 74.

...

The adjusted estimated VE against ED visits/hospitalizations was 95% among patients aged 75 and older, 92% among those with high-risk medical conditions, and 90% against critical outcomes such as intensive care unit admission or mechanical ventilation."

 

(more)

 

https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-vaccine-older-adults-92-protective-against-poor-outcomes-real

 

 

  • Author

What Is Respiratory Syncytial Virus (RSV)?

"Respiratory syncytial virus (RSV) is a common virus that can infect the nose, throat, and lungs, and can make it harder to breathe. It spreads when an infected person coughs, sneezes, or kisses someone, sending tiny droplets into the air. You can also get it by touching something with the virus on it and then touching your eyes, nose, or mouth.

...

While RSV can be serious for very young children and older adults, it can affect people of any age. Roughly 80% of children younger than age 2 years who are hospitalized with RSV do not have risk factors.

...

Burden

Even though RSV often causes mild, cold-like symptoms, it can be serious for infants, toddlers, and older adults, and can lead to severe illness and hospitalization. In the US, RSV is the most common cause of hospitalization in children younger than 1 year old.

 

  • Each year in the US, RSV leads to approximately 2.1 million outpatient visits and 58,000-80,000 hospital stays among children younger than 5 years."

 

https://www.nfid.org/infectious-disease/rsv/

 

Create an account or sign in to comment

Recently Browsing 0

  • No registered users viewing this page.

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.